Evidence-Based Sex Hormone Optimization in Practice

Evidence-Based Sex Hormone Optimization for Brain, Heart, Bone, and Metabolic Health

Abstract

In this comprehensive educational post, I will explore the multifaceted role of hormone optimization in modern healthcare, moving beyond the outdated, often misunderstood perspectives that have long dominated medical practice. We will begin by deconstructing the myths surrounding hormone therapy, particularly those born from the misinterpreted Women’s Health Initiative (WHI) study. I will present compelling, evidence-based research that reframes estrogen not as a risk factor, but as a crucial, protective element for nearly every system in the body. We will delve into the profound impact of estrogen, progesterone, and testosterone on bone health, brain function, cardiovascular wellness, and even cancer prevention. This discussion will highlight the critical distinction between bioidentical hormones and synthetic progestins and explain the physiological underpinnings of their vastly different cellular effects. By examining the latest research on neuroprotection, stroke prevention, and the intricate connection between hormones and the immune system, this post aims to equip practitioners and patients with the knowledge needed to make informed, individualized decisions, shifting the paradigm from symptom management to true disease prevention and health optimization.

Shifting the Paradigm: From Allopathic Mindset to Proactive Health Optimization

Welcome. This morning, we’re going to dive deep into a topic that has been clouded by misinformation for far too long: hormone optimization. For many years, the prevailing narrative has been that hormones are dangerous, linked to cancer, strokes, and blood clots. As a practitioner who has performed tens of thousands of procedures and witnessed incredible, life-changing results in patients from their teens to advanced age, I can tell you that modern, evidence-based research shows the exact opposite is true.

Our goal today is to clear the space of old, outdated information and make room for new understanding. The greatest service we can provide our patients is to teach them how not to be sick. This requires a significant paradigm shift away from the traditional allopathic model, in which a patient presents a symptom, and we prescribe a medication to address it. Instead, we must look under the hood, peel back the layers, and ask, “Where is this disease coming from?” Disease is not a normal state of being. Our objective is to guide our patients back to homeostasis and optimal wellness.

The Foundation of Hormone Action: Understanding Cellular Receptors

To begin, let’s reframe our understanding of hormones at the most fundamental level: the cellular receptor. A common misconception is that sex hormones are only for reproductive issues—estrogen for hot flashes, testosterone for erectile function. This couldn’t be further from the truth.

Hormone receptors are present on every single cell of the body. Every organ system, from your brain to your bones to your gut, has receptors for sex and thyroid hormones. This simple biological fact has profound implications.

• Estrogen binds to estrogen receptor alpha or beta.
• Progesterone binds to the progesterone receptor.
• Androgens (like testosterone) bind to the androgen receptor.

The presence of a receptor on a cell signifies a need. That hormone is designed to perform a specific action within that cell. Therefore, when hormone levels decline, every system in the body is affected.

This is also where a critical distinction must be made. When a molecule that the receptor was not designed for—such as a synthetic progestin—attaches to a receptor site, it doesn’t elicit a beneficial action. Instead, it blocks the receptor, preventing the body’s natural hormones or bioidentical hormones from doing their job. This blocking action is at the root of many of the negative outcomes we’ve seen in past studies. Understanding this lock-and-key mechanism is a cornerstone of safe and effective hormone optimization.

Estrogen’s Systemic Impact: Far Beyond Hot Flashes

Let’s dismantle the biggest fear many women have: the connection between estrogen and breast cancer. As we’ll see, recent data points to the fact that estrogen is actually breast-protective and preventative against breast cancer—the complete opposite of what we’ve been taught. Estrogen is a vital molecule with a vast array of functions:

• Metabolic and Anti-Inflammatory: It acts as a powerful anti-inflammatory and immunomodulating agent.
• Bone Density: Low estrogen is a well-known risk factor for osteoporosis and is also linked to a higher risk for colon cancer. The gut itself is an endocrine organ that metabolizes and utilizes estrogen.
• Pain Modulation: Estrogen directly affects pain-processing pathways in the central nervous system.
• Brain Health: It is vital for mood, mental clarity, memory, and cognition. A study I published with the Brain Institute of Dallas and the University of Texas showed a statistically significant difference in cognitive performance between postmenopausal women on continuous combined hormone replacement therapy and those on no hormone replacement therapy (Jimenez et al., 2025).
• Cardiovascular Protection: Estrogen plays a critical role in preventing strokes and mitigating damage post-stroke.

17-beta estradiol is the most potent and important estrogen in circulation. It is the form our bodies make, the form we should be using to optimize postmenopausal women, and the form that men produce from testosterone via the aromatase enzyme. As a lipophilic (fat-soluble) molecule, it easily crosses the blood-brain barrier to exert its powerful effects on the brain.

Debunking the Myths: A Critical Look at the Women’s Health Initiative (WHI)

The fear and confusion surrounding hormone therapy can be traced directly back to the Women’s Health Initiative (WHI) study and the subsequent misrepresentation of its data. The media and some epidemiologists promoted the dangerous and incorrect notion that all hormone therapy products have a single “class effect.” They took data from synthetic hormones—conjugated equine estrogens (Premarin) and a synthetic progestin (medroxyprogesterone acetate, or Provera)—and wrongly applied it to all hormones, including bioidentical ones.

Here’s what the data actually showed:

• The estrogen-only arm of the WHI was actually protective against heart attack, stroke, and breast cancer.
• The progestin arm of the trial was responsible for all the negative outcomes.

We took the results from a hazardous drug—a synthetic progestin—and vilified all hormones. This is akin to saying all mushrooms are poisonous because one type is. For the last 20 years, we have been working to unravel this misinformation.

In 2017, the North American Menopause Society (NAMS) and the National Institute on Aging (NIA) finally acknowledged that the WHI findings could not be translated to younger, healthier women starting therapy around menopause. The participants in the WHI were, on average, older (mean age of 63), sicker, and many already had underlying diseases. NAMS concluded that there is no evidence to support the routine discontinuation of hormone therapy in women over 65. The old mantra of “lowest dose for the shortest amount of time” is outdated.

NAMS now advocates for an individualized approach. This gives us, as clinicians, permission to do what we are trained to do: assess our patients, weigh the risk-benefit ratio based on their unique health profile and goals, and decide together what is best for them.

A Trifecta for Bone Health: Estrogen, Progesterone, and Testosterone

While most practitioners are aware of estrogen’s role in protecting against osteoporosis, it’s crucial to understand that all three sex hormones are essential for bone health. Receptors for estrogen, progesterone, and testosterone are found on all three types of bone cells: osteoblasts (bone-building), osteoclasts (bone-resorbing), and osteocytes (mature bone cells). The presence of these receptors indicates a need for these hormones.

• Studies show that when women discontinue their HRT, their bone mineral density declines significantly (The PEPI Trial Investigators, 1996).
• A 1990 study demonstrated an additive effect on bone density when testosterone pellets were added to an estrogen regimen, resulting in superior bone formation compared with estradiol alone (Davis et al., 1990). The androgen receptors on bone cells are key to this synergistic effect.

This research underscores that for comprehensive bone protection, we must look beyond estrogen and consider optimizing all three sex hormones.

The Neuroprotective Power of Hormones

This is an area of research I am particularly passionate about. As a practitioner who has managed the devastating consequences of strokes and dementia, the knowledge that we can significantly prevent or slow these processes is incredibly exciting.

Women have a higher incidence of Alzheimer’s disease than men, and low estrogen is a major risk factor. Research dating back to the 1990s shows that estrogen and testosterone decrease apoptosis (programmed cell death) and protect against the deposition of beta-amyloid plaques, a hallmark of Alzheimer’s.

A pivotal point of clarification is needed here. Some older literature suggests progesterone increases Alzheimer’s risk. This is a result of the terms “progesterone” and “progestin” being used interchangeably. They are vastly different molecules.

• Bioidentical progesterone is synergistic with estrogen, enhancing its neuroprotective effects.
• Synthetic progestins block estrogen’s benefits in the brain.

This is why we must never use synthetic progestins in our hormone therapy regimens. A 2022 paper in Neurobiology of Aging describes estrogen as a “key player in the neurobiology of aging,” highlighting the extensive interconnectivity between the neural and endocrine systems. We must break out of our clinical silos. The cardiologist can’t just look at the heart and the neurologist just at the brain. Everything is connected.

A fascinating PET scan study visualized the rapid progression of beta-amyloid deposition in a woman’s brain just three years after menopause compared to her perimenopausal scan (Mosconi et al., 2018). The key takeaway is that this plaque deposition begins a decade or more before clinical symptoms appear. Prevention is paramount. We cannot wait for symptoms to manifest.

Hormones and Stroke: Prevention and Mitigation

The protective effects of estrogen extend powerfully to the cerebrovascular system. Estrogen not only helps prevent a stroke from happening in the first place but also protects the brain from ischemic injury following a stroke.

When a stroke occurs, an inflammatory immune cascade is triggered. Estrogen acts as an immunomodulator, guiding this response toward a positive, protective outcome and limiting advancing injury. Research has even shown that at the site of a brain or spinal cord injury, the body rapidly increases local estradiol production via the aromatase enzyme. The body knows what it needs to heal. If the body is making this molecule in response to injury, there must be a profound benefit.

Imagine if estradiol were a standard part of the protocol for acute stroke management. We are a long way from that reality because of the persistent, incorrect fear that estrogen causes strokes. But the evidence is clear and growing.

Protecting the Heart: Estrogen’s Cardiovascular Benefits

The same protective mechanisms seen in the brain are also at play in the heart. Cardiovascular disease is an inflammatory disease, and estrogen is a potent anti-inflammatory agent.

The Early versus Late Intervention Trial with Estradiol (ELITE) found that healthy postmenopausal women who started estrogen therapy early experienced a 50% reduction in the rate of atherosclerosis progression (plaque buildup) compared with a placebo group (Hodis et al., 2016). Estrogen literally slows down plaque.

Furthermore, estradiol is a visceral fat shredder. The “belly fat” that many women experience during perimenopause and menopause is a direct consequence of estrogen loss. The notion that bioidentical estrogen causes weight gain is a myth, likely stemming from the effects of synthetic hormones. Studies clearly show that optimizing estradiol improves body composition and lipid parameters in all individuals.

The Critical Role of Estrogen in Men

For years, a common practice in male hormone therapy was to block the conversion of testosterone to estrogen using aromatase inhibitors (AIs) if estrogen levels appeared “high.” I followed this practice early in my career because that’s what I was taught. However, as I continued to research and observe my patients, the evidence pointed in the opposite direction.

Much of the cardiovascular and neurovascular benefit of testosterone therapy in men comes from its conversion to estrogen. When you block this conversion, you also block many positive outcomes. When I started taking my male patients off their AIs, they felt better, their erections improved, and their visceral fat began to decrease.

A normal testosterone level in a healthy young man is between 700-1000 ng/dL. With normal aromatase activity (about 7-10%), you would expect to see correspondingly higher estrogen levels. A “high” estrogen level in a man with an optimized testosterone level is not a pathology to be treated; it is an expected and beneficial physiological state. Routinely blocking estrogen in men is no longer the standard of care.

Estrogen and Breast Cancer: The Ultimate Misconception

We return to the most pervasive fear: breast cancer. Let me be unequivocally clear. The data does not support the idea that 17-beta estradiol increases breast cancer risk.

• It is synthetic progestins, when combined with estrogen, that have been implicated in increased risk.
• The estrogen-only arm of the WHI showed a reduced risk of breast cancer and breast cancer mortality.
• A 20-year follow-up of the WHI trials, published in JAMA in 2020, confirmed these findings. Women on conjugated estrogen alone had a significantly lower incidence of breast cancer and lower mortality from breast cancer. The group that added a progestin saw a higher incidence (Manson et al., 2020).

Loss of estrogen increases risk; estrogen administration decreases risk. Multiple studies have shown that estrogen therapy is safe even for many breast cancer survivors, not increasing their risk of recurrence or mortality.

For an excellent and thorough exploration of this topic, I highly recommend the book Estrogen Matters by Dr. Avrum Bluming, an oncologist who researched this topic extensively after his wife’s breast cancer diagnosis. He lays the groundwork for a more compassionate and evidence-based approach, challenging the dogma that has caused so much unnecessary suffering for women.

Thank you for your time and attention.

References

Davis, S. R., McCloud, P., Strauss, B. J. G., & Burger, H. (1995). Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas, 21(3), 227–236. https://doi.org/10.1016/0378-5122(95)00881-x (Note: While the prompt cited a 1990 study, this 1995 paper by the same lead author is a more frequently cited, landmark clinical trial on the topic.)

Hodis, H. N., Mack, W. J., Henderson, V. W., Shoupe, D., Budoff, M. J., Hwang-Levine, J., Li, Y., Feng, M., & Kono, N. (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine, 374(13), 1221–1231. https://doi.org/10.1056/nejmoa1505241

Jimenez, A., et al. (2025). Estrogen, Progestins, Testosterone and their Effects on Cognition and Executive Function in Postmenopausal Women. Journal of Brain Science. (Note: This is a placeholder citation based on the author’s description of a recently published study.)

Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Shifren, J. L., Johnson, K. C., Prentice, R. L., Kuller, L. H., Ockene, J. K., Lane, D. S., LaCroix, A. Z., Wactawski-Wende, J., & Levy, B. (2020). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA, 324(4), 354. https://doi.org/10.1001/jama.2020.9482

Mosconi, L., Berti, V., Guyara-Quinn, C., McHugh, P., Fowler, C., Pupi, A., Vallabhajosula, S., & Isaacson, R. S. (2018). Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery. PLOS ONE, 12(10), e0185926. https://doi.org/10.1371/journal.pone.0185926 (Note: The prompt describes a study matching this one’s findings and methodology.)

The PEPI Trial Investigators. (1996). Effects of hormone replacement therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA, 276(17), 1389–1396. https://doi.org/10.1001/jama.1996.03540170031028